Vol. 6 No. 4 (2026): April
Reimbursement Reviews

Acalabrutinib (Calquence)

decorative image of the issue cover

Published April 15, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses acalabrutinib (Calquence), 100 mg tablets, oral.
  • Indication: in combination with venetoclax for the treatment of patients with previously untreated CLL.